Pharmabiz

Addex Therapeutics’ drug candidate GABAB PAM shows solid anti-tussive activity in bleomycin IPF-related chronic cough model

Addex Therapeutics’ drug candidate GABAB PAM shows solid anti-tussive activity in bleomycin IPF-related chronic cough model: Geneva, Switzerland Saturday, May 2, 2026, 18:00 Hrs ...
Healio

Allosteric modulator nonsuperior to placebo in Parkinson’s disease

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
Nasdaq

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Geneva, Switzerland, May 12, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...
Pharmabiz

Addex Therapeutics’ GABAB PAM candidate shows robust anti-tussive activity in non-human primate chronic cough model

Addex Therapeutics’ GABAB PAM candidate shows robust anti-tussive activity in non-human primate chronic cough model: Geneva, Switzerland Wednesday, April 22, 2026, 18:00 Hrs [IS ...
Seeking Alpha

Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
FierceBiotech

Gain hopes to prove Parkinson's drug's potential next year after phase 1 win for allosteric modulator

Gain Therapeutics has set its sights on proving the effectiveness of its Parkinson’s disease therapy next year after the brain-penetrant small molecule demonstrated “peripheral target engagement” in a ...

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued ...
BioWorld

Items Tagged with 'muscarinic M4 receptor positive allosteric modulators'

Dysregulation of cholinergic neurotransmission through muscarinic receptors, particularly the M1 and M4 subtypes, has been implicated in the pathophysiology of schizophrenia. Muscarinic M4 receptor ...

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ...